Polaris today announced that it has completed a series of agreements that culminates in acquiring the intellectual property of Phoenix Pharmacologics, Inc. Polaris now holds the worldwide rights, excluding Taiwan and China, to ADI‑PEG 20 and worldwide rights, excluding Taiwan, to Uricase-PEG 20. ADI‑PEG 20 is a pegylated form of the enzyme arginine deiminase, a biotherapeutic agent currently in Phase 2 clinical trials for the treatment of both hepatocellular cancer and metastatic melanoma. Uricase-PEG 20 is a pegylated form of urate oxidase, a biotherapeutic agent that has successfully completed a Phase 1 clinical study and is now being developed for the treatment of refractory gout, hyperuricemia, and tumor lysis syndrome.
With this purchase, Polaris has also acquired the rights to several early development stage biotherapeutic agents, including TNF-PEG 20 and Histidase-PEG 20, and novel potent small molecule inhibitors of casein kinase 2. These acquisitions provide Polaris with a promising pipeline, particularly in the anticancer therapeutic area.
About Polaris Group
Polaris Group is a privately held multinational biopharmaceutical company specializing in the research and development of protein drugs to treat cancer and other debilitating diseases. The company also utilizes a rational structure-based approach for the design of novel small molecule inhibitors of cancer-related protein targets.